Advancing CAR-T Therapies: Our Four Strategic Directions

CAR-T cell therapy represents one of the most transformative breakthroughs in modern medicine. By re-engineering a patient’s own immune cells to recognize and destroy cancer cells, CAR-T has opened new possibilities for treating tumors that were once difficult to manage. Our organization is pioneering innovative CAR-T solutions across four major therapeutic directions:

1. Targeted Therapy for Post-operative Recovery in Liver Cancer Patients

For patients undergoing minimally invasive surgery for liver cancer, recurrence and residual cancer cells remain a major clinical challenge. We are developing targeted drug therapies combined with advanced immune-modulation, designed to:

  • Support rapid post-operative recovery

  • Reduce tumor relapse risk

  • Precisely target and eliminate remaining malignant cells

This approach enhances long-term survival outcomes while improving the patient’s quality of life.

2. Infusion of Mesenchymal Stem Cells and Autologous Immune Cells

Our second initiative focuses on personalized cellular immunotherapy. By reinfusing mesenchymal stem cells (MSCs) along with the patient’s own immune cells, we aim to:

  • Promote tissue regeneration

  • Strengthen immune system defense

  • Enhance anti-tumor immune responses

This combination therapy provides a powerful and personalized boost to the patient’s recovery and long-term immune health.

3. Long-term Preservation of Autologous Stem Cells and Immune Cells

As cellular therapies continue to advance, preserving high-quality cells at a younger and healthier stage becomes increasingly valuable. We offer a cutting-edge cell banking service:

  • Storage of a patient’s stem cells and immune cells

  • A 20-year preservation plan with a total cost of 50,000 RMB

This strategic investment ensures that patients have access to their own biological resources for future treatments, supporting proactive health management and personalized medicine.

4. CAR-T Therapy for Leukemia

CAR-T therapy has shown groundbreaking success in hematological malignancies, especially leukemia. We are expanding the clinical application of CAR-T cells to:

  • Precisely target leukemia-associated antigens

  • Achieve high remission rates

  • Provide new options for patients unresponsive to conventional treatments

Our goal is to deliver safer, more effective, and more accessible CAR-T solutions for all eligible leukemia patients.

Our Mission

We are committed to pushing the boundaries of cell-based cancer therapies—combining scientific innovation, personalized treatment, and long-term health planning. Through our four strategic directions, we aim to bring advanced immunotherapy benefits to more patients around the world.